Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis

American Journal of Physiology - Renal Physiology

Volumn 298, Issue 3, 2010, Pages

  Zhang, Jiandong ^a,b   Noble, Nancy A ^b   Border, Wayne A ^b   Huang, Yufeng ^b,c  

^a SOUTHEAST UNIVERSITY   (China)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c Fibrosis Research Laboratory   (United States)

Author keywords

Mas receptor; Renal fibrosis; Renin angiotensin system

Indexed keywords

ANGIOTENSIN[1-7]; COLLAGEN TYPE 1; FIBRONECTIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; MALE; MESANGIUM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIODIC ACID SCHIFF STAIN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 77649125799     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00548.2009     Document Type: Article

References (47)

1. Al-Maghrebi M, Benter IF, Diz DI. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res 59: 263-268, 2009.
2. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 290: H684-H691, 2006.
3. Benter IF, Yousif MH, Dhaunsi GS, Kaur J, Chappell MC, Diz DI. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 28: 25-33, 2008.
4. Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 50: 596-599, 2007.
5. Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney. Scientific World Journal 9: 522-535, 2009.
6. Ebrahim H, Evans DJ. Antibody induced injury to podocytes with proteinuria and foot process swelling in a transgenic (T16) mouse. Int J Exp Pathol 80: 77-86, 1999.
7. Ferreira AJ, Oliveira TL, Castro MC, Almeida AP, Castro CH, Caliari MV, Gava E, Kitten GT, Santos RA. Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci 81: 916-923, 2007.
8. Gaedeke J, Peters H, Noble NA, Border WA. Angiotensin II, TGF-β and renal fibrosis. Contrib Nephrol 135: 153-160, 2001.
9. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292: H736-H742, 2007.
10. 1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol 294: F1287-F1295, 2008.
11. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA. A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 19: 329-338, 2008.
12. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112: 379-388, 2003.
13. Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-beta 1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 72: 45-52, 2007.
14. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta 1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 69: 105-113, 2006.
15. Ingelfinger JR. Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr Opin Nephrol Hypertens 18: 79-84, 2009.
16. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289: H2356-H2363, 2005.
17. Ji H, Menini S, Zheng W, Pesce C, Wu X, Sandberg K. Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17 beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats. Exp Physiol 93: 648-657, 2008.
18. Katovich MJ, Grobe JL, Raizada MK. Angiotensin-(1-7) as an antihypertensive, antifibrotic target. Curr Hypertens Rep 10: 227-232, 2008.
19. Laviades C, Varo N, Diez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 36: 517-522, 2000.
20. Mizuiri S, Hemmi H, Arita M, Ohashi Y, Tanaka Y, Miyagi M, Sakai K, Ishikawa Y, Shibuya K, Hase H, Aikawa A. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 51: 613-623, 2008.
21. Moritz KM, Campbell DJ, Wintour EM. Angiotensin-(1-7) in the ovine fetus. Am J Physiol Regul Integr Comp Physiol 280: R404-R409, 2001.
22. Narita I, Border WA, Ketteler M, Ruoslahti E, Noble NA. L-Arginine may mediate the therapeutic effects of low protein diets. Proc Natl Acad Sci USA 92: 4552-4556, 1995.
23. Noble NA, Border WA. Angiotensin II in renal fibrosis: should TGF-b rather than blood pressure be the therapeutic target? Semin Nephrol 17: 455-466, 1997.
24. Okuda S, Nakamura T, Yamamoto T, Ruoslahti E, Border WA. Dietary protein restriction rapidly reduces transforming growth factor b1 expression in experimental glomerulonephritis. Proc Natl Acad Sci USA 88: 9765-9769, 1991.
25. Pendergrass KD, Averill DB, Ferrario CM, Diz DI, Chappell MC. Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2 Lewis rat. Am J Physiol Renal Physiol 290: F1497-F1506, 2006.
26. Peters H, Border WA, Noble NA. Angiotensin II blockade and lowprotein diet produce additive therapeutic effects in experimental glomerulonephritis. Kidney Int 57: 1493-1501, 2000.
27. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54: 1570-1580, 1998.
28. Pinheiro SV, Ferreira AJ, Kitten GT, DA Silveira KD, DA Silva DA, Santos SH, Gava E, Castro CH, Magalhaes JA, DA Mota RK, Botelho-Santos GA, Bader M, Alenina N, Santos RA, Simoes E Silva AC. Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 75: 1184-1193, 2009.
29. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 74: 1610-1616, 2008.
30. Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten GT, Ferreira AJ. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 47: 996-1002, 2006.
31. Santos RA, Ferreira AJ. Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens 16: 122-128, 2007.
32. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 93: 519-527, 2008.
33. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100: 8258-8263, 2003.
34. Shao Y, He M, Zhou L, Yao T, Huang Y, Lu LM. Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury. Acta Pharmacol Sin 29: 829-837, 2008.
35. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ. Captopril-induced reduction of serum levels of transforming growth factor-beta 1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 34: 818-823, 1999.
36. Silveira KD, Santos RA, Barroso LC, Lima CX, Teixeira MM, Silva AC. The oral agonist of angiotensin-(1-7) Mas receptor, AVE 0991, exerts renoprotective and anti-inflammatory effects in an experimental model of nephrotic syndrome (Abstract). In: World Congress of Nephrology 2009, Milan, Italy, p. M388.
37. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289: H1560-H1566, 2005.
38. Trask AJ, Ferrario CM. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 25: 162-174, 2007.
39. van der Wouden EA, Henning RH, Deelman LE, Roks AJ, Boomsma F, de Zeeuw D. Does angiotensin (1-7) contribute to the anti-proteinuric effect of ACE-inhibitors. J Renin Angiotensin Aldosterone Syst 6: 96-101, 2005.
40. Velez JC, Bland AM, Arthur JM, Raymond JR, Janech MG. Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes. Am J Physiol Renal Physiol 293: F398-F407, 2007.
41. Velez JC, Ryan KJ, Harbeson CE, Bland AM, Budisavljevic MN, Arthur JM, Fitzgibbon WR, Raymond JR, Janech MG. Angiotensin I is largely converted to angiotensin (1-7) and angiotensin (2-10) by isolated rat glomeruli. Hypertension 53: 790-797, 2009.
42. Wenzel UO, Thaiss F, Panzer U, Schneider A, Schwietzer G, Helmchen U, Stahl RA. Effect of renovascular hypertension on experimental glomerulonephritis in rats. J Lab Clin Med 134: 292-303, 1999.
43. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17: 3067-3075, 2006.
44. Yoshida M, Naito Y, Urano T, Takada A, Takada Y. L-158,809 and [D-Ala(7)]-angiotensin I/II (1-7) decrease PAI-1 release from human umbilical vein endothelial cells. Thromb Res 105: 531-536, 2002.
45. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 16: 1733-1741, 2005.
46. Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA. Combining TGF-β inhibition and angiotensin II blockade results in enhanced anti-fibrotic effect. Kidney Int 66: 1774 -1784, 2004.
47. Zhang H, Wada J, Hida K, Tsuchiyama Y, Hiragushi K, Shikata K, Wang H, Lin S, Kanwar YS, Makino H. Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J Biol Chem 276: 17132-17139, 2001.